| Nal-IRI with 5-fluorouracil and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer, a phase 2 study of the AIO hepatobiliary and YMO cancer groups (NIFE-AIO-YMO HEP-0315) - updated survival and QoL results. |
|
|
| Oncol Res Treat 47 (suppl 1): 66 |
|
2024 |
|
Hepatobiliäre Tumoren
|
|
|
| doi.org/10.1159/000535363 |
|
|
| Steroid and antibiotic treatment are associated with diverse immunotherapy efficacy: A pooled analysis of the RAMONA, INTEGA, OPTIM, ELDORANDO, FORCE, TITAN-RCC and TITAN-TCC trials of the German AIO study group |
|
|
| Ann Oncol 35 (Supplement 2, 1067P): 707 |
|
2024 |
| doi.org/10.1016/j.annonc.2024.08.1125 |
|
|
| Progression-free and overall survival of patients with SCLC and ECOG performance status 0-1 – Data from the Clinical Research platform Into molecular testing, treatment and outcome of (non-) Small cell lung carcinoma Patients (CRISP; AIO-TRK-0315). |
|
|
| Oncol Res Treat 47(suppl 2): 199-200 (P448) |
|
2024 |
| doi.org/10.1159/000540557 |
|
|
| Predictors of Immune-Related Adverse Events in Immune Checkpoint Inhibitor Therapy – A pooled analysis of the RAMONA, INTEGA, OPTIM, ELDORANDO, FORCE, TITAN-RCC and TITAN-TCC studies of the German AIO study group. |
|
|
| Oncol Res Treat 47(suppl 2): 45 (V239) |
|
2024 |
| doi.org/10.1159/000540557 |
|
|
| Steroid and Antibiotic Treatment are associated with diverse Immunotherapy Efficacy - A Pooled Analysis of the RAMONA, INTEGA, OPTIM, ELDORANDO, FORCE, TITAN-RCC and TITAN-TCC Trials of the German AIO Study Group. |
|
|
| Oncol Res Treat 47(suppl 2): 317 (P1106) |
|
2024 |
| doi.org/10.1159/000540557 |
|
|
| Steroid and antibiotic treatment are associated with diverse immunotherapy efficacy a pooled analysis of the RAMONA, INTEGA, OPTIM, ELDORANDO, FORCE, TITAN-RCC and TITAN-TCC trials of the German AIO study group |
|
|
| Z Gastroenterol 62(09): 711-2 |
|
2024 |
| doi.org/10.1055/s-0044-1789880 |
|
|
| A randomized phase II study of durvalumab and tremelimumab compared to doxorubicin in patients with advanced or metastatic soft tissue sarcoma (MEDISARC, AIO-STS-0415). |
Gruenwald V. |
Viktor Grünwald |
| Ann Oncol 34 (Supplement 2, S1331-2, LBA90) |
Abstract |
2023 |
|
Weichteilsarkome
|
MEDISARC |
AIO-STS-0415 |
| doi.org/10.1016/j.annonc.2023.10.092 |
|
|
| Efficacy of a tailored approach with nivolumab (N) and nivolumab+ipilimumab (N+I) as immuno-therapeutic boost in metastatic urothelial carcinoma (mUC): Final results of TITAN-TCC. |
|
|
| Ann Oncol 34 (Supplement 2, S1207-8, 2372P) |
|
2023 |
|
Urothelkarzinom
|
|
|
| doi.org/10.1016/j.annonc.2023.09.1021 |
|
|
| Tailored immunotherapy approach with nivolumab with or without ipilimumab in patients with advanced transitional cell carcinoma after platinum-based chemotherapy (TITAN-TCC): a multicentre, single-arm, phase 2 trial. |
|
|
| Lancet Oncol 24 (4): 347-59 |
|
2023 |
|
Urothelkarzinom
|
|
|
| www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00053-0/fulltext |
|
|
| Testing for and frequency of EGFR and ALK alterations in patients with early and locally advanced non-small cell lung cancer in Germany. Results from the prospective German Registry CRISP (AIO-TRK-0315). |
|
|
| Oncol Res Treat 46 (suppl.5): 10-11 |
|
2023 |
|
Thorakale Onkologie
|
|
|
| doi.org/10.1159/000533576 |
|
|
